Unit:
Speciality Infectious DiseasesLibrary of the School of Health Sciences
Author:
Tsakiris Antonios-Chrysovalantis
Supervisors info:
Ευάγγελος Ι. Γιαμαρέλλος-Μπουρμπούλης, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Εριφύλη Χατζιαγγελάκη, Καθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ
Σταυρούλα Παπαδόδημα,Αναπληρώτρια Καθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ
Original Title:
Μεταβολή ιικού φορτίου και έκβαση COVID-19
Translated title:
Change in viral load and COVID-19 outcomes
Summary:
Evolution of pneumonia by the new SARS-CoV-2 coronavirus (also known as COVID-19) is unpredictable. That is why it is necessary an indicator that could effectively help in forecasting the clinical course of patients, as well as the risk of transmission and spread of virus mutations. In many studies the possibility of viral load of SARS-CoV-2 in both respiratory secretions as well as in the blood to be used as an indicator of their severity patients. It has been shown that measuring viral load could assess the progression of the patients' course, as there is a correlation with comorbidities of patients and with the inflammatory response. Beyond However, a higher viral load has been shown to be associated with a higher risk transmission and can be used to determine the probability horizontal and vertical transmission given their rapid dispersion transmission of virus mutations. The above makes it necessary to find a drug that will reduces the viral load and consequently will lead to more effective treatment of COVID-19 infection. Clarithromycin, which has been and continues to be the subject of interest and research, it is known that in addition to its antibacterial properties, it has an immunomodulatory effect and anti-inflammatory action. For this reason it has been suggested in the past as a treatment option for viral respiratory infections, which have inflammatory background. Previous studies have shown that clarithromycin effectively reduces the viral load of H5N1 and H7N9 viruses of avian influenza in an animal model. In addition, in patients who received a combination of B-lactam and clarithromycin for severe pneumonia community, the mortality rate after 28 days was 20.8%, while in patients receiving a combination of B-lactam and azithromycin percentage mortality rate was 33.8%
Main subject category:
Health Sciences
Keywords:
Viral load, COVID-19
